Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Communications With CMS To Get Outside Review Under EpiPen Settlement

Executive Summary

Corporate integrity agreement requires Mylan to have an independent body review its drug classifications and US best price determinations; settlement resolves claims Mylan misclassified EpiPen to underpay rebates. Sanofi acted as whistleblower in case.

Advertisement

Related Content

Teva To Launch First Generic EpiPen In 'Coming Months'; FDA Heralds Approval Of Complex Product
Teva To Launch First Generic EpiPen In 'Coming Months'; FDA Heralds Approval Of Complex Product
You Work In The Pharmaceutical Industry; Here's Why You Should Care About The Novartis Payments
Mylan Set To Develop Biosimilar Botox In Deal With Revance
Mylan Set To Develop Biosimilar Botox In Deal With Revance
Gilead Asks Supreme Court To Restrict False Claims Act Cases
Azar To Come Up With 'Balanced Solution' To Drug Pricing, CMS Administrator Says
EpiPen Pricing Got Mylan In Hot Water; Now Sanofi Is Taking Firm To Court
Fast Like EpiPen: Mylan Reaches Quick Settlement Over Medicaid Rebates

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel